Norovirus gastroenteritis, increased understanding and future antiviral options

Current Opinion in Investigational Drugs

Volumn 9, Issue 2, 2008, Pages 146-151

  Tan, M ^a   Jiang, X ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antiviral agent; Calicivirus; Drug design; Gastroenteritis; Norovirus

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; GAMMA INTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RNA POLYMERASE; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CRYSTAL STRUCTURE; DRUG SCREENING; GASTROENTERITIS; HOST CELL; HUMAN; IMMUNE RESPONSE; NOROVIRUS; PROTEIN STRUCTURE; REVIEW; RNA REPLICATION; VIROTHERAPY; VIRUS CELL INTERACTION;

ANTIVIRAL AGENTS; CALICIVIRIDAE INFECTIONS; ENZYME INHIBITORS; GASTROENTERITIS; HUMANS; NOROVIRUS; VIRUS ATTACHMENT;

EID: 38849144654     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Atmar RL, Estes MK: The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am (2006) 35(2):275-290.
2. Green KY, Chanock RM, Kapikian AZ: Human caliciviruses. In: Field's Virology. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (Eds), 4th Edition, Lippincott Williams & Wilkins, Philadelphia, PA, USA (2001) 2:841-874. • A summary of the basic knowledge of human caliciviruses (noroviruses and sapoviruses).
3. Tan M, Jiang X: Norovirus-host interaction: Implications for disease control and prevention. Expert Rev Mol Med (2007) 9(19):1-22. • A review of advances in the understanding of norovirus and host cell interaction, and the implication for disease control and prevention.
4. Jiang X, Graham DY, Wang KN, Estes MK: Norwalk virus genome cloning and characterization. Science (1990) 250(4987):1580-1583.
5. Estes MK, Prasad BV, Atmar RL: Noroviruses everywhere: Has something changed? Curr Opin Infect Dis (2006) 19(5):467-474. • A review of the widespread nature of noroviruses.
6. Tan M, Jiang X: Norovirus and its histo-blood group antigen receptors: An answer to a historical puzzle. Trends Microbiol (2005) 13(6):285-293.
7. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK: X-ray crystallographic structure of the Norwalk virus capsid. Science (1999) 286(5438):287-290.
8. Cao S, Lou Z, Tan M, Chen Y, Liu Y, Zhang Z, Zhang XC, Jiang X, Li X, Rao Z: Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol (2007) 81(11):5949-5957. •• The first study to elucidate the crystal structure of the HBGA-binding sites of the norovirus.
9. Tan M, Farkas T, Jiang X: Molecular pathogenesis of human norovirus. In: Host Gene Responses to RNA Virus Infection. Yang DC (Ed), World Scientific Publishing Co Inc, NJ, USA (2008):in press.
10. Chan M, Wong Y, Sung J, Leung W: Ex vivo support and suppression of human norovirus RNA replication. International Calicivirus Conference (2007) 3:Abs S6-8.
11. Straub TM, Honer zu Bentrup K, Orosz-Coghlan P, Dohnalkova A, Mayer BK, Bartholomew RA, Valdez CO, Bruckner-Lea CJ, Gerba CP, Abbaszadegan M, Nickerson CA: In vitro cell culture infectivity assay for human noroviruses. Emerg Infect Dis (2007) 13(3):396-403. •• The first report of the organoid model to support human norovirus RNA replication.
12. Fankhauser RL, Monroe SS, Noel JS, Humphrey CD, Bresee JS, Parashar UD, Ando T, Glass RI: Epidemiologic and molecular trends of 'norwalk-like viruses' associated with outbreaks of gastroenteritis in the United States. J Infect Dis (2002) 186(1):1-7.
13. Fankhauser RL, Noel JS, Monroe SS, Ando T, Glass RI: Molecular epidemiology of 'norwalk-like viruses' in outbreaks of gastroenteritis in the United States. J Infect Dis (1998) 178(6):1571-1578.
14. Ko G, Jiang ZD, Okhuysen PC, DuPont HL: Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to noroviruses. J Med Virol (2006) 78(6):825-828.
15. Ko G, Garcia C, Jiang ZD, Okhuysen PC, Belkind-Gerson J, Glass RI, DuPont HL: Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. J Clin Microbiol (2005) 43(12):6126-6129.
16. Chapin AR, Carpenter CM, Dudley WC, Gibson LC, Pratdesaba R, Torres O, Sanchez D, Belkind-Gerson J, Nyquist I, Karnell A, Gustafsson B et al: Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrhea. J Clin Microbiol (2005) 43(3):1112-1117.
17. Okhuysen PC: Current concepts in travelers' diarrhea: Epidemiology, antimicrobial resistance and treatment. Curr Opin Infect Dis (2005) 18(6):522-526.
18. Lopman BA, Reacher MH, Van Duijnhoven Y, Hanon FX, Brown D, Koopmans M: Viral gastroenteritis outbreaks in Europe, 1995-2000. Emerg Infect Dis (2003) 9(1):90-96.
19. Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C, Griffin PM, Tauxe RV: Food-related illness and death in the United States. Emerg Infect Dis (1999) 5(5):607-625. • A summary of the importance of noroviruses in food-related illnesses in the US.
20. Hardy ME: Norovirus protein structure and function. FEMS Microbiol Lett (2005) 253(1):1-8. • A review of the structure and function of individual norovirus proteins, and a discussion of the potential roles these proteins may play in the virus replication cycle.
21. Ho DD: How far can you knock down HIV? An interview with David D Ho, MD. Interview by Mark Mascolini. J Int Assoc Physicians AIDS Care (1997) 3(6):40-44.
22. Ho DD: Perspectives series: Host/pathogen interactions. Dynamics of HIV-1 replication in vivo. J Clin Invest (1997) 99(11):2565-2567.
23. Haraguchi Y, Sakurai H, Hussain S, Anner BM, Hoshino H: Inhibition of HIV-1 infection by zinc group metal compounds. Antiviral Res (1999) 43(2):123-133.
24. Bourne N, Stegall R, Montano R, Meador M, Stanberry LR, Milligan GN: Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob Agents Chemother (2005) 49(3):1181-1183.
25. Greenberg SB, Harris D, Giles P, Martin RR, Wallace RJ Jr: Inhibition of Chlamydia trachomatis growth in McCoy, HeLa, and human prostate cells by zinc. Antimicrob Agents Chemother (1985) 27(6):953-957.
26. Katz BA, Clark JM, Finer-Moore JS, Jenkins TE, Johnson CR, Ross MJ, Luong C, Moore WR, Stroud RM: Design of potent selective zinc-mediated serine protease inhibitors. Nature (1998) 391(6667):608-612.
27. Zeitler CE, Estes MK, Venkataram Prasad BV: X-ray crystallographic structure of the norwalk virus protease at 1.5-A resolution. J Virol (2006) 80(10):5050-5058. • Elucidation of the atomic structure of Norwalk virus protease and its catalytic active site.
28. Nakamura K, Someya Y, Kumasaka T, Ueno G, Yamamoto M, Sato T, Takeda N, Miyamura T, Tanaka N: A norovirus protease structure provides insights into active and substrate binding site integrity. J Virol (2005) 79(21):13685-13693. • This study provides the first crystal structure of noroviral protease.
29. Schneider G, Bohm HJ: Virtual screening and fast automated docking methods. Drug Discov Today (2002) 7(1):64-70. • An introduction into the computational virtual screening and fast automated docking methods.
30. Bissantz C, Bernard P, Hibert M, Rognan D: Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins (2003) 50(1):5-25.
31. O'Reilly EK, Kao CC: Analysis of RNA-dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure. Virology (1998) 252(2):287-303.
32. Rohayem J, Jager K, Robel I, Scheffler U, Temme A, Rudolph W: Characterization of norovirus 3Dpol RNA-dependent RNA polymerase activity and initiation of RNA synthesis. J Gen Virol (2006) 87(9):2621- 2630.
33. Rohayem J, Robel I, Jäger K, Scheffler U, Rudolph W: Protein-primed and de novo initiation of RNA synthesis by norovirus 3Dpol. J Virol (2006) 80(14):7060-7069. • This paper describes the development of a functional assay for noroviral polymerase.
34. Ng KK, Pendás-Franco N, Rojo J, Boga JA, Machin A, Alonso JM, Parra F: Crystal structure of norwalk virus polymerase reveals the carboxyl terminus in the active site cleft. J Biol Chem (2004) 279(16):16638-16645. • This study provides the first crystal structure of norwalk virus polymerase.
35. Jones LA, Clancy LE, Rawlinson WD, White PA: High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity. Antimicrob Agents Chemother (2006) 50(9):3019-3027.
36. Fullerton SW, Blaschke M, Coutard B, Gebhardt J, Gorbalenya A, Canard B, Tucker PA, Rohayem J: Structural and functional characterization of sapovirus RNA-dependent RNA polymerase. J Virol (2006) 81(4):1858-1871.
37. Ng KK, Cherney MM, Vazquez AL, Machin A, Alonso JM, Parra F, James MN: Crystal structures of active and inactive conformations of a caliciviral RNA-dependent RNA polymerase. J Biol Chem (2002) 277(2):1381- 1387.
38. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Stewart P, LePendu J, Baric R: Human susceptibility and resistance to norwalk virus infection. Nat Med (2003) 9(5):548-553. •• This paper presents the first direct evidence to link norovirus infection with human HBGA.
39. Hutson AM, Atmar RL, Estes MK: Norovirus disease: Changing epidemiology and host susceptibility factors. Trends Microbiol (2004) 12(6):279-287.
40. Le Pendu J: Histo-blood group antigen and human milk oligosaccharides: Genetic polymorphism and risk of infectious diseases. Adv Exp Med Biol (2004) 554:135-143.
41. Ravn V, Dabelsteen E: Tissue distribution of histo-blood group antigens. APMIS (2000) 108(1):1-28.
42. Jiang X, Huang P, Zhong W, Tan M, Farkas T, Morrow AL, Newburg DS, Ruiz-Palacios GM, Pickering LK: Human milk contains elements that block binding of noroviruses to human histo-blood group antigens in saliva. J Infect Dis (2004) 190(10):1850-1859.
43. Morrow AL, Ruiz-Palacios GM, Altaye M, Jiang X, Guerrero ML, Meinzen-Derr JK, Farkas T, Chaturvedi P, Pickering LK, Newburg DS: Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J Pediatr (2004) 145(3):297-303.
44. Huang P, Farkas T, Marionneau S, Zhong W, Ruvoën-Clouet N, Morrow AL, Altaye M, Pickering LK, Newburg DS, LePendu J, Jiang X: Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: Identification of 4 distinct strain-specific patterns. J Infect Dis (2003) 188(1):19-31.
45. Huang P, Farkas T, Zhong W, Tan M, Thornton S, Morrow AL, Jiang X: Norovirus and histo-blood group antigens: Demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol (2005) 79(11):6714-6722.
46. Feng X, Jiang X: Library screen for inhibitors targeting norovirus binding to histo-blood group antigen receptors. Antimicrob Agents Chemother (2007) 51(1):324-331. • This paper describes the screening of a compound library using VLP and saliva-based binding assay. Over a dozen lead compounds were identified that effectively inhibited norovirus VLP binding to saliva samples.
47. Choi J, Hutson AM, Estes MK, Prasad BVV: Recognition of histo blood group antigens by Norwalk virus capsid protein. International Calicivirus Conference (2007) 3:Abs S1-4.
48. Zhang Y, Yao Q, Xia C, Jiang X, Wang PG: Trapping norovirus by glycosylated hydrogels: A potential oral antiviral drug. ChemMedChem (2006) 1(12):1361-1366.
49. Tan M, Jiang X: The P domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J Virol (2005) 79(22):14017-14030.
50. Tan M, Meller J, Jiang X: C-terminal arginine cluster is essential for receptor binding of norovirus capsid protein. J Virol (2006) 80(15):7322-7331.
51. Tamura M, Natori K, Kobayashi M, Miyamura T, Takeda N: Inhibition of attachment of virions of norwalk virus to mammalian cells by soluble histone molecules. Arch Virol (2003) 148(9):1659-1670.
52. McCann KB, Lee A, Wan J, Roginski H, Coventry MJ: The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures. J Appl Microbiol (2003) 95(5):1026-1033.
53. Toniutto P, Fabris C, Pirisi M: Antiviral treatment of hepatitis C. Expert Opin Pharmacother (2006) 7(15):2025-2035.
54. Saito S, Heller T, Yoneda M, Takahashi H, Nakajima A, Liang JT: Lifestyle-related diseases of the digestive system: A new in vitro model of hepatitis C virion production: Application of basic research on hepatitis C virus to clinical medicine. J Pharmacol Sci (2007) 105(2):138-144.
55. Neyts J: Selective inhibitors of hepatitis C virus replication. Antiviral Res (2006) 71(2-3):363-371.
56. Glenn JS: Molecular virology of the hepatitis C virus: Implication for novel therapies. Clin Liver Dis (2005) 9(3):353-369.
57. Chang KO, Sosnovtsev SV, Belliot G, King AD, Green KY: Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line. Virology (2006) 353(2):463-473. • A study reporting the production of a stable norovirus replication system in human cell lines of human (Huh-7) or hamster (BHK21) origin.
58. Chang KO, George DW: Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells. J Virol (2007) 81(22):12111-12118. • A study reporting the usefulness of a norovirus replication system in the estimation of noroviral antiviral agent activity.
59. Mumphrey SM, Changotra H, Moore TN, Heimann-Nichols ER, Wobus CE, Reilly MJ, Moghadamfalahi M, Shukla D, Karst SM: Murine norovirus 1 infection is associated with histopathological changes in immunocompetent hosts, but clinical disease is prevented by STAT1-dependent interferon responses. J Virol (2007) 81(7):3251-3263.
60. Karst SM, Changotra H, Jia YL: The mechanisms by which interferon responses control murine norovirus infection. International Calicivirus Conference (2007) 3:Abs S7-7.
61. Straub TM, Bartholomew R, Wahl J, Wunschel D: In vitro replication of human noroviruses and host response observed in a 3-D model of small intestinal epithelium. International Calicivirus Conference (2007) 3:Abs S7-5.
62. Guix S, Asanaka M, Katayama K, Crawford SE, Neill FH, Atmar RL, Estes MK: Norwalk virus RNA is infectious in mammalian cells. J Virol (2007) 81(22):12238-12248.
63. Katayama K, Hansman GS, Oka T, Ogawa S, Takeda N: Investigation of norovirus replication in a human cell line. Arch Virol (2006) 151(7):1291-1308.
64. Asanaka M, Atmar RL, Ruvolo V, Crawford SE, Neill FH, Estes MK: Replication and packaging of norwalk virus RNA in cultured mammalian cells. Proc Natl Acad Sci USA (2005) 102(29):10327-10332.
65. Cheetham S, Souza M, Meulia T, Grimes S, Han MG, Saif LJ: Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs. J Virol (2006) 80(21):10372-10381. •• The first report of a gnotobiotic pig as an animal model for human norovirus replication.
66. Souza M, Cheetham SM, Azevedo MS, Costantini V, Saif LJ: Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain). J Virol (2007) 81(17):9183-9192.